Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
December 3, 2018
Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies
PALO ALTO, Calif., Dec. 3, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare ...
December 3, 2018
Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update
LIVONIA, Mich., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
December 3, 2018
Theravance Biopharma Announces Closing of Private Placement of $250 Million of 9% Non-Recourse Notes
DUBLIN, Dec. 3, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" and together with its subsidiaries, the "Company") today announced the closing of a private ...
December 3, 2018
Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA® (ZX008) in Dravet Syndrome
EMERYVILLE, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) --  Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare diseases, announced today that ...
December 3, 2018
Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study
NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (EYEN) today announced that it has completed patient enrollment in its Phase III MIST-1 study ...
December 3, 2018
Mainstay Medical to Showcase ReActiv8 and Key Clinical Data at the 13th German Spine Congress of the DWG
DUBLIN--(BUSINESS WIRE)--Regulatory News: Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on commercializing ReActiv8®, ...
November 29, 2018
TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs
SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
November 29, 2018
ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies
BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (ARQL) today announced that it will host a call to discuss the updated safety, PK, biomarker and anti-tumor activity data from ...
November 29, 2018
RedHill Biopharma to Present at BMO 2018 Prescriptions for Success Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
November 29, 2018
Athenex Announces Licensing Agreement with PharmaEssentia for Rights to Oradoxel (Oral Docetaxel) in Certain Asian Territories
BUFFALO, N.Y., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
November 29, 2018
Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2018 Annual Meeting
EMERYVILLE, Calif., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare diseases, today announced that ...
November 29, 2018
NOX Announces Positive Data from CEP-1 Study of Veyonda®
SYDNEY, Australia, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Noxopharm (ASX:NOX) announces the final results from its Phase 1b CEP-1 trial evaluating its lead immuno-oncology/radio-enhancer drug ...
November 29, 2018
BioTime to Present at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer of ...
November 29, 2018
BioTime Announces Distribution of AgeX Therapeutics Shares
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that the registration statement on Form 10, including ...
November 29, 2018
InspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard™ EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)
TEL AVIV, Israel, Nov. 29, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention ...
November 29, 2018
Spring Bank Announces Additional Pre-Clinical Data on Its Second-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy
HOPKINTON, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
November 29, 2018
Elements Behavioral Health Announces Adoption of Deep Transcranial Magnetic Stimulation (Deep TMS) for Depression in Tennessee Facility
NUNNELLY, Tenn., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Elements Behavioral Health, the owner of behavioral health programs located throughout the United States, announced today that ...
November 28, 2018
Sierra Oncology to Host Analyst Call Highlighting Clinical Data on Momelotinib's Anemia Benefit
VANCOUVER , Nov. 27, 2018 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment ...
November 28, 2018
Prometic Provides Corporate Update
LAVAL, QC , Nov 28, 2018 /CNW Telbec/ -  Prometic Life Sciences Inc. (PLI.TO) (PFSCF)("Prometic" or the "Corporation") has previously announced a series of initiatives to ...
November 28, 2018
Mustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy Data at AACR Special Conference on Tumor Immunology and Immunotherapy
NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies based on proprietary ...
Page 24 of 138